Compare CLF & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLF | GRFS |
|---|---|---|
| Founded | 1847 | 1940 |
| Country | United States | Spain |
| Employees | 25000 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.0B |
| IPO Year | 2006 | 2008 |
| Metric | CLF | GRFS |
|---|---|---|
| Price | $12.56 | $7.32 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 2 |
| Target Price | ★ $10.43 | $10.15 |
| AVG Volume (30 Days) | ★ 12.3M | 354.2K |
| Earning Date | 04-20-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,610,000,000.00 | N/A |
| Revenue This Year | $8.76 | $4.49 |
| Revenue Next Year | $2.64 | $6.42 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $6.96 |
| 52 Week High | $16.70 | $10.23 |
| Indicator | CLF | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 35.57 |
| Support Level | $11.98 | $7.33 |
| Resistance Level | $12.71 | $8.41 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 62.13 | 5.76 |
Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.